david gandara, md, talks about the potential impact of immunotherapy in 1st line nsclc
Published 8 years ago • 77 plays • Length 1:32
Download video MP4
Download video MP3
Similar videos
-
0:41
julie brahmer, md, talks about the potential impact of immunotherapy in 1st line nsclc
-
0:35
david ettinger, md, talks about impact of immunotherapy in 1st line metastatic nsclc patients
-
0:46
david gandara, md, discusses considerations when choosing between immunotherapy and chemotherapy
-
0:58
david gandara, md,, discusses pd-l1 expression and selecting the appropriate agent in nsclc patients
-
1:55
dr. gandara on the impact of immunotherapy on the tumor microenvironment in lung cancer
-
0:31
david gandara, md, discusses pembrolizumab vs docetaxel for previously treated nsclc patients
-
1:41
david r. gandara, md, discusses drug sequencing as a result of keynote 189 and 42 results
-
30:53
immunotherapy side effects: what patients need to know with dr. jeffery weber
-
45:36
patient to patient: what you need to know about cancer immunotherapy
-
15:23
made impossible dreams come true | nivedha r.m. | tedxwestfordunisharjah
-
1:49
immunotherapy and beyond for lung cancer prevention
-
7:31
outcomes of first-line pembrolizumab monotherapy for pd-l1–positive metastatic nsclc
-
15:53
ev-103 study by dr. jonathan rosenberg led to the fda approval of enfortumab pembrolizumab
-
11:43
how immunotherapy could help us beat cancer | deepta bhattacharya | tedxuarizona
-
33:11
brain cancer and immunotherapy with dr. david reardon
-
0:55
the potential of targeted and immune therapies in sclc
-
0:58
dr. david gandara spotlights the giants of cancer care
-
1:40
dr. gandara discusses the oak trial for lung cancer
-
0:56
pembrolizumab and the significance of pd-l1 for lung cancer
-
37:38
learn the basics of immunotherapy from david reardon, m.d.
-
1:02
dr. gandara on the mystic trial for lung cancer
-
0:25
david ettinger, md, on choosing between immunotherapy and chemotherapy in metastatic nsclc patients
Clip.africa.com - Privacy-policy